These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 32626999)
1. TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma. Zhang W; Zheng X; Xie S; Zhang S; Mao J; Cai Y; Lu X; Chen W; Ni H; Xie L Mol Med Rep; 2020 Aug; 22(2):1187-1194. PubMed ID: 32626999 [TBL] [Abstract][Full Text] [Related]
2. TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT. Chen X; Zhou Z; Tang P; Du F; Wang S; Yao J; Zhang S; Huang J; Lu X; Chen W; Yu X; Liu Y; Liu H Curr Cancer Drug Targets; 2024 Feb; ():. PubMed ID: 38415469 [TBL] [Abstract][Full Text] [Related]
3. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells. Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286 [TBL] [Abstract][Full Text] [Related]
4. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. Tajiri H; Uruno T; Shirai T; Takaya D; Matsunaga S; Setoyama D; Watanabe M; Kukimoto-Niino M; Oisaki K; Ushijima M; Sanematsu F; Honma T; Terada T; Oki E; Shirasawa S; Maehara Y; Kang D; Côté JF; Yokoyama S; Kanai M; Fukui Y Cell Rep; 2017 May; 19(5):969-980. PubMed ID: 28467910 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766 [TBL] [Abstract][Full Text] [Related]
6. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis. Vasko R; Mueller GA; von Jaschke AK; Asif AR; Dihazi H Eur J Pharmacol; 2011 Nov; 670(1):50-7. PubMed ID: 21924258 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene. Sun X; Lou L; Zhong K; Wan L Exp Biol Med (Maywood); 2017 Jun; 242(12):1299-1305. PubMed ID: 28429654 [TBL] [Abstract][Full Text] [Related]
8. The supression of DOCK family members by their specific inhibitors induces the cell fusion of human trophoblastic cells. Kiyokawa E; Shoji H; Daikoku T Biochem Biophys Res Commun; 2020 Sep; 529(4):1173-1179. PubMed ID: 32819582 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial-mesenchymal transition. Chen DJ; Chen W; Jiang H; Yang H; Wang YC; Chen JH Drug Des Devel Ther; 2016; 10():2845-2853. PubMed ID: 27660415 [TBL] [Abstract][Full Text] [Related]
10. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation. Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222 [TBL] [Abstract][Full Text] [Related]
11. Cyanidin Curtails Renal Cell Carcinoma Tumorigenesis. Liu X; Zhang D; Hao Y; Liu Q; Wu Y; Liu X; Luo J; Zhou T; Sun B; Luo X; Xu J; Wang Q; Yang Z; Li L Cell Physiol Biochem; 2018; 46(6):2517-2531. PubMed ID: 29742507 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Morais C; Gobe G; Johnson DW; Healy H Apoptosis; 2010 Apr; 15(4):412-25. PubMed ID: 19856104 [TBL] [Abstract][Full Text] [Related]
13. Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation. Pan Y; Li X; Duan J; Yuan L; Fan S; Fan J; Xiaokaiti Y; Yang H; Wang Y; Li X Mol Pharmacol; 2015; 87(3):378-90. PubMed ID: 25488183 [TBL] [Abstract][Full Text] [Related]
14. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. Feng J; Lu H; Ma W; Tian W; Lu Z; Yang H; Cai Y; Cai P; Sun Y; Zhou Z; Feng J; Deng J; Shu Y; Qu K; Jia W; Gao P; Zhang H Protein Cell; 2022 Nov; 13(11):825-841. PubMed ID: 35217990 [TBL] [Abstract][Full Text] [Related]
15. Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression. Li W; Yang D; Zhang Y; Zhao S; Li D; Liu M Oncol Rep; 2020 Nov; 44(5):1985-1996. PubMed ID: 33000253 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma. Wu X; Liu D; Gao X; Xie F; Tao D; Xiao X; Wang L; Jiang G; Zeng F Cell Physiol Biochem; 2017; 41(5):1947-1956. PubMed ID: 28391274 [TBL] [Abstract][Full Text] [Related]
17. PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Hueber PA; Waters P; Clark P; Eccles M; Goodyer P Kidney Int; 2006 Apr; 69(7):1139-45. PubMed ID: 16609680 [TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627 [TBL] [Abstract][Full Text] [Related]
19. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling. Toth C; Funke S; Nitsche V; Liverts A; Zlachevska V; Gasis M; Wiek C; Hanenberg H; Mahotka C; Schirmacher P; Heikaus S Cell Commun Signal; 2017 May; 15(1):16. PubMed ID: 28464919 [TBL] [Abstract][Full Text] [Related]
20. Livin enhances chemoresistance in head and neck squamous cell carcinoma. Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]